Regeneron Pharmaceuticals Inc. (REGN) In The Drugs Spotlight Today

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Regeneron Pharmaceuticals ( REGN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.2%. By the end of trading, Regeneron Pharmaceuticals rose $3.06 (1.6%) to $188.47 on light volume. Throughout the day, 391,662 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 736,900 shares. The stock ranged in a price between $183.20-$188.50 after having opened the day at $185.06 as compared to the previous trading day's close of $185.41. Other companies within the Drugs industry that increased today were: Anacor Pharmaceuticals ( ANAC), up 14%, Oxygen Biotherapeutics ( OXBT), up 13.6%, Biocryst Pharmaceuticals ( BCRX), up 12.9%, and Novogen ( NVGN), up 12.8%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $17.65 billion and is part of the health care sector. The company has a P/E ratio of 27.4, above the S&P 500 P/E ratio of 17.7. Shares are up 8.4% year to date as of the close of trading on Friday. Currently there are eight analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and six rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, Prima Biomed ( PBMD), down 17.4%, Cardium Therapeutics ( CXM), down 11.4%, DARA Biosciences ( DARA), down 9.9%, and Bacterin International Holdings ( BONE), down 9.7%, were all laggards within the drugs industry with Medivation ( MDVN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)